Medications used to treat patients with an enlarged prostate have been found to not be associated with the increased risk of hip fracture, it has been noted.
In news that may interest those seeking long term care, a study in the October 6th issue of JAMA revealed that the intake of 5-a reductase inhibitors did not cause this threat to rise, Eurekalert reports.
Enlarged prostates - benign prostatic hyperplasia - is a common condition among aging males and it is believed that eight million US males aged between 50 and 79 years of age will meet the guidelines for treatment consideration by 2010.
Researchers from Kaiser Permanente in southern California found that there was no dose-response relationship between exposure to the treatment and the risk of suffering a fracture to the hip bone and that such medication may, in fact, reduce the threat.
The authors concluded: "While presumably this lower risk is related to hormonal mechanisms, further understanding of the biological mechanisms underlying this phenomenon may lead to new insights that can be exploited for preventive measures."
Meanwhile, drinking a moderate amount of red wine has been found to lower the risk of developing lung cancer in men - and particularly those who smoke - according to Kaiser Permanente researchers.